Myriad Genetics Q2 2026 Earnings: Financial Results, Revenue, and Key Highlights from Form 10
Myriad Genetics filed its Form 10-Q for the quarter ended June 30, 2026. The company reported Q2 2026 net loss of $43.2 million, or $0.46 per share, versus $330.5 million in Q2 2025. Total assets fell to $638.9 million and stockholders’ equity to $303.9 million from Dec. 31, 2025. Shares outstanding rose to 95.6 million.
How this was made
The 30-second read
Why it matters
Traders can use the reported loss reduction versus Q2 2025 alongside balance-sheet deterioration (assets and equity down) and share count increase to reassess near-term risk and valuation expectations.
Market read
A fresh SEC filing provides updated financial metrics: Q2 net loss of $43.2M (improved vs $330.5M a year ago) but declining assets/equity and dilution from share issuance.
What to watch
The article emphasizes assets and equity declines but does not quantify cash balance, operating cash flow, or debt maturities, which are often the real determinants of near-term risk.
Background
The piece summarizes Myriad Genetics’ Q2 2026 Form 10-Q filed for the quarter ended June 30, 2026.
Ticker impact
Myriad Genetics filed its Q2 2026 Form 10-Q, reporting Q2 net loss of $43.2M and six-month net loss of $77.3M.
Likely choppy reaction, with upside sentiment from reduced net loss offset by concerns over declining assets/equity and dilution.
The article provides concrete P&L and balance-sheet direction (losses down YoY, assets and equity down since year-end 2025, shares outstanding up), but it lacks guidance, cash runway, or segment drivers that would anchor a decisive repricing.
Market effects
Signals ongoing profitability pressure typical of genomics/diagnostics firms, with investors likely focused on cash burn and dilution risk.
Limited, primarily affects US small/mid-cap biotech/genetics sentiment.
Low, no cross-border deal, regulator action, or global macro linkage described.
Counterpoint
The YoY net loss improvement may reflect one-time timing or expense classification rather than durable operating leverage, so the market may discount it without clearer drivers.
Key entities
- companyMyriad Genetics, Inc.
US-listed genetics company that filed its Q2 2026 Form 10-Q and reported net losses, asset/equity declines, and share count growth.
- filingForm 10-Q (quarter ended June 30, 2026)
Primary disclosure source for the financial highlights cited in the article.
